PRAXIS PRECISION MEDICINES I (PRAX) Stock Price, Forecast & Analysis
NASDAQ:PRAX • US74006W2070
PRAX Key Statistics, Chart & Performance
The current stock price of PRAX is 348.345 USD. In the past month the price increased by 16.55%. In the past year, price increased by 787.85%.
PRAX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to PRAX. When comparing the yearly performance of all stocks, PRAX is one of the better performing stocks in the market, outperforming 99.66% of all stocks.
PRAX Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PRAX. PRAX has a great financial health rating, but its profitability evaluates not so good.
PRAX Financial Highlights
Over the last trailing twelve months PRAX reported a non-GAAP Earnings per Share(EPS) of -13.46. The EPS decreased by -31.06% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -32.33% | ||
| ROE | -34.54% | ||
| Debt/Equity | 0 |
PRAX Forecast & Estimates
21 analysts have analysed PRAX and the average price target is 619.14 USD. This implies a price increase of 77.74% is expected in the next year compared to the current price of 348.345.
For the next year, analysts expect an EPS growth of 0.6% and a revenue growth 38343.6% for PRAX
PRAX Ownership
PRAX Latest News, Press Relases and Analysis
PRAX Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.92 | 403.74B | ||
| AMGN | AMGEN INC | 17.12 | 206.168B | ||
| GILD | GILEAD SCIENCES INC | 16.61 | 183.174B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.04 | 123.671B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.89 | 81.636B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.49 | 43.973B | ||
| INSM | INSMED INC | N/A | 33.829B | ||
| NTRA | NATERA INC | N/A | 29.154B | ||
| BIIB | BIOGEN INC | 12.8 | 28.637B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.83 | 20.386B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About PRAX
Company Profile
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. The company is headquartered in Boston, Massachusetts and currently employs 116 full-time employees. The company went IPO on 2020-10-16. The firm is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
Company Info
PRAXIS PRECISION MEDICINES I
99 High Street, 30th Floor
Boston MASSACHUSETTS 02142 US
CEO: Marcio Souza
Employees: 116
Phone: 16173008460
PRAXIS PRECISION MEDICINES I / PRAX FAQ
What does PRAXIS PRECISION MEDICINES I do?
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company, which engages in the genetic epilepsies into the development of therapies for central nervous system, or CNS, disorders characterized by neuronal excitation-inhibition imbalance. The company is headquartered in Boston, Massachusetts and currently employs 116 full-time employees. The company went IPO on 2020-10-16. The firm is applying genetic insights to the discovery and development of therapies for neurological disorders through two platforms, using its understanding of shared biological targets and circuits in the brain. Its platform includes Cerebrum, a small-molecule platform, which utilizes deep understanding of neuronal excitability and neuronal networks and applies a series of computational and experimental tools to develop orally available precision therapies, and Solidus, an antisense oligonucleotide platform, is an efficient, targeted precision medicine discovery and development engine anchored on a proprietary, computational methodology. The Company’s product candidates include ulixacaltamide, vormatrigine, relutrigine, PRAX-080, and others.
What is the stock price of PRAXIS PRECISION MEDICINES I today?
The current stock price of PRAX is 348.345 USD. The price increased by 1.64% in the last trading session.
Does PRAX stock pay dividends?
PRAX does not pay a dividend.
What is the ChartMill rating of PRAXIS PRECISION MEDICINES I stock?
PRAX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
What sector and industry does PRAXIS PRECISION MEDICINES I belong to?
PRAXIS PRECISION MEDICINES I (PRAX) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for PRAXIS PRECISION MEDICINES I?
The Revenue of PRAXIS PRECISION MEDICINES I (PRAX) is expected to grow by 38343.6% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.
What is the employee count for PRAX stock?
PRAXIS PRECISION MEDICINES I (PRAX) currently has 116 employees.